Pulmonary Embolism International THrOmbolysis trial:A reduced dose of thrombolytic treatment for patients with intermediatehigh-risk acute pulmonary embolism: a randomized, placebo-controlled trial

06/07/2020 to 06/07/2026

In patients with intermediate-risk pulmonary embolism, thrombolytic treatment is associated with a reduction in the combined risk of hemodynamic decompensation and death but also with an increased risk of major and intracranial bleeding. The effect of thrombolytic treatment on the risk of death is still controversial in these patients. Previous studies suggest that reduced dose of thrombolytic treatment is as effective as the full dosage but is associated with a decrease in the risk of bleeding. In this study, we will assess the efficacy and safety of a reduced dosage of thrombolytic therapy in patients with intermediate-high-risk acute pulmonary embolism.